Critique Pembrolizumab (Keytruda): CADTH Reimbursement Recommendation: Sign: In combination with chemotherapy, with the therapy of adult people with locally recurrent unresectable or metastatic triple-negative breast cancer who have not acquired prior chemotherapy for metastatic disease and whose tumours Specific programmed cell Loss of life-ligand 1 (blended constructive score ≥ 10) https://alfrede567rqn7.blogdosaga.com/profile